Durvalumab, Cediranib ± Olaparib in Recurrent Ovarian Cancer
In a groundbreaking phase II proof-of-concept clinical trial published recently in Nature Communications, researchers led by Tabata, Huang, and Giudice have unveiled promising therapeutic insights...
















